Literature DB >> 23472867

BCL-2 inhibition: stemming the tide of myeloid malignancies.

Leah J Hogdal1, Anthony Letai.   

Abstract

Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. As reported in this issue of Cell Stem Cell, Lagadinou et al. (2013) and Goff et al. (2013) support selective targeting of LSCs by small molecule antagonists of anti-apoptotic BCL-2 family proteins.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23472867      PMCID： PMC3705714          DOI： 10.1016/j.stem.2013.02.006

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  12 in total

1.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

Authors:  Mark F van Delft; Andrew H Wei; Kylie D Mason; Cassandra J Vandenberg; Lin Chen; Peter E Czabotar; Simon N Willis; Clare L Scott; Catherine L Day; Suzanne Cory; Jerry M Adams; Andrew W Roberts; David C S Huang
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

2.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

3.  Programmed anuclear cell death delimits platelet life span.

Authors:  Kylie D Mason; Marina R Carpinelli; Jamie I Fletcher; Janelle E Collinge; Adrienne A Hilton; Sarah Ellis; Priscilla N Kelly; Paul G Ekert; Donald Metcalf; Andrew W Roberts; David C S Huang; Benjamin T Kile
Journal:  Cell       Date:  2007-03-23       Impact factor: 41.582

4.  BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

Authors:  Victoria Del Gaizo Moore; Krysta D Schlis; Stephen E Sallan; Scott A Armstrong; Anthony Letai
Journal:  Blood       Date:  2007-12-04       Impact factor: 22.113

5.  A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.

Authors:  M Vogler; D Dinsdale; X-M Sun; K W Young; M Butterworth; P Nicotera; M J S Dyer; G M Cohen
Journal:  Cell Death Differ       Date:  2008-02-29       Impact factor: 15.828

Review 6.  Cancer stem cells: lessons from leukemia.

Authors:  Jean C Y Wang; John E Dick
Journal:  Trends Cell Biol       Date:  2005-09       Impact factor: 20.808

7.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Authors:  Andrew W Roberts; John F Seymour; Jennifer R Brown; William G Wierda; Thomas J Kipps; Seong Lin Khaw; Dennis A Carney; Simon Z He; David C S Huang; Hao Xiong; Yue Cui; Todd A Busman; Evelyn M McKeegan; Andrew P Krivoshik; Sari H Enschede; Rod Humerickhouse
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

8.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

9.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.

Authors:  T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

10.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633
View more
  4 in total

Review 1.  Reactive oxygen species in eradicating acute myeloid leukemic stem cells.

Authors:  Hui Zhang; Hai Fang; Kankan Wang
Journal:  Stem Cell Investig       Date:  2014-06-07

Review 2.  Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.

Authors:  Clark W Distelhorst
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-07-25       Impact factor: 4.739

3.  Evaluation and critical assessment of putative MCL-1 inhibitors.

Authors:  S Varadarajan; M Vogler; M Butterworth; D Dinsdale; L D Walensky; G M Cohen
Journal:  Cell Death Differ       Date:  2013-07-05       Impact factor: 15.828

Review 4.  Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe.

Authors:  Cristina Panuzzo; Aleksandar Jovanovski; Barbara Pergolizzi; Lucrezia Pironi; Serena Stanga; Carmen Fava; Daniela Cilloni
Journal:  Int J Mol Sci       Date:  2020-05-30       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.